Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events

Abstract We surveyed the performance of ponatinib, as salvage therapy, in a real-world setting of chronic phase chronic myeloid leukemia (CML-CP). Among 55 consecutive patients (median age 49 years) with relapsed/refractory CML-CP, 35 (64%) had failed ≥3 tyrosine kinase inhibitors (TKIs), 35 (64%) w...

Full description

Bibliographic Details
Main Authors: Maymona G. Abdelmagid, Aref Al-Kali, Mark R. Litzow, Kebede H. Begna, William J. Hogan, Mirinal S. Patnaik, Shahrukh K. Hashmi, Michelle A. Elliott, Hassan Alkhateeb, Omer S. Karrar, Farah Fleti, Mohammed H. Elnayir, Candido E. Rivera, Hemant S. Murthy, James M. Foran, Mohamed A. Kharfan-Dabaja, Talha Badar, David S. Viswanatha, Kaaren K. Reichard, Naseema Gangat, Ayalew Tefferi
Format: Article
Language:English
Published: Nature Publishing Group 2023-08-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00891-x

Internet

https://doi.org/10.1038/s41408-023-00891-x

Similar Items